Microsatellite Instability clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
at UC Irvine UCLA UCSD UCSF
Our lead scientists for Microsatellite Instability research studies include Gregory Daniels, MD John Fruehauf, MD Katy Tsai, MD Bartosz Chmielowski, MD.
Last updated: